NASDAQ:RNA Avidity Biosciences Q2 2026 Earnings Report $8.95 -0.61 (-6.38%) As of 09/18/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Avidity Biosciences EPS ResultsActual EPS-$1.18Consensus EPS -$1.42Beat/MissBeat by +$0.24One Year Ago EPSN/AAvidity Biosciences Revenue ResultsActual Revenue$3.00 millionExpected Revenue$0.67 millionBeat/MissBeat by +$2.34 millionYoY Revenue GrowthN/AAvidity Biosciences Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateThursday, August 13, 2026Conference Call Time4:00PM ETUpcoming EarningsAvidity Biosciences' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Avidity Biosciences Earnings HeadlinesNovartis RNA drug falls short in rare muscle disease studySeptember 9, 2026 | finance.yahoo.comAtrium Therapeutics to Participate in Upcoming Investor ConferencesSeptember 2, 2026 | prnewswire.comYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type of finance to build lasting wealth. Legendary investor Joel Greenblatt calls it 'the closest thing to a perpetual motion machine you will ever see.' One investor famously turned 50000 dollars into 900 million using this approach. Porter Stansberry breaks down its origins and mechanics in a new free documentary.September 20 at 1:00 AM | Porter & Company (Ad)Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 20, 2026 | prnewswire.comAtrium Therapeutics Reports Second Quarter 2026 Financial ResultsAugust 13, 2026 | prnewswire.comAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationAugust 13, 2026 | prnewswire.comSee More Avidity Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avidity Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your email. Email Address About Avidity BiosciencesAvidity Biosciences (NASDAQ:RNA) is a biopharmaceutical company focused on developing RNA therapeutics for diseases that have historically been difficult to treat with conventional drug-delivery methods. Founded in 2012 and headquartered in San Diego, California, the company develops medicines intended to address genetic disorders, with an emphasis on diseases affecting muscles. Avidity’s proprietary Antibody Oligonucleotide Conjugate (AOC) platform combines the targeting capabilities of monoclonal antibodies with the gene-modifying potential of oligonucleotides, including small interfering RNA and antisense oligonucleotides. The approach is designed to help deliver RNA-based medicines into specific tissues and cells, where they can influence the production or processing of disease-related proteins. The company’s pipeline includes delpacibart etedesiran, also known as del-desiran or AOC 1001, an investigational therapy for myotonic dystrophy type 1. Other clinical and preclinical programs have targeted conditions such as facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy. Avidity conducts research and clinical development activities through collaborations and studies involving patients and medical institutions in multiple regions. Sarah Boyce serves as the company’s president and chief executive officer.View Avidity Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
